Last updated: November 8, 2026
Paragard T 380A is a mature, single-product intrauterine contraceptive device with durable demand, limited direct U.S. competition in the copper-IUD segment, and no publicly disclosed standalone revenue stream. Its commercial value comes from brand recognition, clinical familiarity, manufacturing know-how, and distribution rather than a clearly identifiable active patent monopoly. CooperSurgical owns and markets Paragard in the United States after acquiring the product from Teva Pharmaceuticals for approximately $1.1 billion in 2017. The product’s financial trajectory is therefore best assessed through Cooper Companies’ Women’s Health segment, procedure volumes, pricing, litigation costs, and competitive substitution by hormonal IUDs.
Paragard T 380A Market Dynamics, Financial Trajectory, Competition and Exclusivity
What is Paragard T 380A and how does it work?
Paragard T 380A is a hormone-free, copper-bearing intrauterine contraceptive manufactured and marketed in the United States by CooperSurgical. The device consists of a T-shaped polyethylene frame with copper wire on the vertical stem and copper sleeves on the horizontal arms. It prevents pregnancy primarily through the local spermicidal effect of copper ions in the uterine environment.
The U.S. prescribing information identifies Paragard as an intrauterine contraceptive for women of reproductive potential. Its labeled duration is up to 10 years, although clinical use and professional guidance have often treated copper IUD contraception as extending beyond the original labeled period in some circumstances. The device also has noncontraceptive positioning as a hormone-free option and can be used for emergency contraception when inserted within the applicable clinical window.[1]
Paragard is a medical device, not a conventional pharmaceutical drug. It is regulated through FDA medical-device requirements rather than the New Drug Application and Orange Book framework used for drugs.
What is the FDA regulatory status of Paragard?
Paragard is an FDA-approved Class III medical device. The original U.S. regulatory record is associated with PMA P840001, reflecting the premarket approval pathway applicable to high-risk intrauterine contraceptive devices.[2]
| Regulatory attribute |
Paragard status |
| Product |
Paragard T 380A |
| Active technology |
Copper-bearing intrauterine device |
| FDA category |
Class III medical device |
| U.S. regulatory pathway |
Premarket approval |
| FDA approval period |
Approved in 1984 |
| U.S. manufacturer and marketer |
CooperSurgical |
| Drug application |
No NDA |
| Orange Book listing |
No |
| Biosimilar pathway |
Not applicable |
| Primary use |
Long-acting reversible contraception |
The device’s regulatory position creates a higher entry threshold than a simple generic-drug launch. A competitor would generally need its own FDA authorization, supporting safety and effectiveness data, quality-system compliance, manufacturing validation, and postmarket surveillance capability.
When does Paragard lose exclusivity?
Paragard does not have a conventional drug-patent exclusivity date. Its commercial protection is based on device approval, manufacturing capabilities, brand position, clinical adoption, distribution, and regulatory execution.
The original technology is decades old, and the core copper-IUD concept is not protected by a current, broad U.S. patent monopoly that would prevent all competing copper-IUD products. Patent expiration has therefore reduced the legal barrier to entry. The remaining barriers are primarily regulatory and operational.
Paragard also does not receive the type of five-year new chemical entity exclusivity or three-year clinical-investigation exclusivity associated with certain FDA-approved drugs. There is no conventional Hatch-Waxman Paragraph IV framework for launching a competing Paragard device.
Does Paragard have Orange Book patents?
No. Paragard is not listed in the FDA Orange Book as a drug product, and its U.S. exclusivity cannot be analyzed through Orange Book-listed patents or Paragraph IV certifications.
A competing device manufacturer would instead pursue the applicable FDA device pathway. Depending on product design and substantial equivalence, that pathway could involve a 510(k), a PMA, or another device-specific regulatory route. A copper IUD with materially different design or clinical characteristics would likely face a more demanding review than a minor modification to an already authorized device.
How large is the U.S. market for copper IUDs?
Copper IUD demand is driven by long-acting reversible contraception adoption, preference for hormone-free birth control, reproductive-health policy, and physician access. The addressable market is smaller than the broader IUD market because hormonal IUDs dominate many U.S. contraceptive practices.
Paragard’s differentiation is clear:
| Factor |
Paragard |
Hormonal IUDs |
| Hormones |
None |
Levonorgestrel-based |
| Duration |
Up to 10 years on U.S. labeling |
Product-dependent |
| Menstrual effect |
May increase bleeding and cramping |
Often reduces bleeding |
| Emergency contraception |
Established use |
Product-specific evidence and guidance |
| Main competitors |
Other copper IUDs, where available |
Mirena, Liletta, Kyleena and Skyla |
| Commercial positioning |
Hormone-free, long duration |
Long duration with local progestin |
The strongest demand segments are patients seeking hormone-free contraception, those who want long duration without daily adherence, and patients seeking a reversible method that does not require recurring prescription refills.
The main demand constraint is tolerability. Increased menstrual bleeding and dysmenorrhea can lead to discontinuation and may direct patients toward levonorgestrel-releasing IUDs.
Who competes with Paragard?
In the United States, Paragard has historically occupied a distinctive position as the principal FDA-approved copper IUD. Its most important commercial competition is therefore indirect.
Hormonal IUD competition
Bayer’s Mirena and Kyleena, Organon’s Liletta, and Bayer’s Skyla compete for the same long-acting contraception decision. These products can have stronger appeal among patients seeking lighter periods or reduced menstrual pain.
Implant competition
Organon’s Nexplanon competes for patients prioritizing long duration and high efficacy. Nexplanon requires a subdermal insertion and uses etonogestrel, creating a different adverse-effect and bleeding profile.
Short-acting contraception
Oral contraceptives, vaginal rings, patches, injections, condoms, and sterilization remain substitutes. Their recurring-use structure can support IUD demand because Paragard has no monthly prescription or pharmacy-refill requirement after insertion.
International copper-IUD suppliers
Outside the United States, multiple copper-IUD products are marketed by regional manufacturers. International competition is more fragmented because national regulatory approvals, reimbursement systems, and product designs vary.
What is the financial trajectory of Paragard?
Cooper Companies does not generally disclose Paragard revenue as a separate public reporting line. The product is included within CooperSurgical and the company’s Women’s Health operations. This limits precise assessment of unit sales, gross margin, operating profit, and annual growth.
The 2017 acquisition provides the clearest valuation reference. Teva sold Paragard to CooperSurgical for approximately $1.1 billion, reflecting the value of an established contraceptive franchise with long product life, physician familiarity, and recurring procedure demand.[3]
The financial profile has several defining characteristics:
- Revenue is procedure-driven rather than prescription-driven. Sales depend on insertion volumes, clinician access, reimbursement, clinic capacity, and patient demand.
- The device can generate revenue over a long clinical life because replacement is measured in years rather than months.
- Gross-margin potential is supported by a durable, specialized product, but manufacturing quality requirements and litigation exposure can reduce returns.
- Sales growth is likely to be moderate rather than driven by a major new indication or a short-term launch cycle.
- CooperSurgical’s broader product portfolio reduces dependence on Paragard alone, but it also prevents investors from isolating the product’s performance from other women’s-health businesses.
Cooper Companies’ medical-device reporting provides the appropriate public-market lens. Paragard should be evaluated as a cash-generating franchise within CooperSurgical, not as a separately reported pharmaceutical asset.[4]
What patent litigation and product-liability risks affect Paragard?
The principal legal risk associated with Paragard has been product-liability litigation alleging device breakage, difficult removal, and related injuries. Plaintiffs have alleged that the device can fracture during removal and that the manufacturer failed to provide adequate warnings or design protections.
These claims are distinct from patent litigation. A product-liability case does not establish that a competitor can launch a legally equivalent device, and a patent settlement would not be the expected mechanism for resolving the main Paragard litigation exposure.
The litigation risk has financial implications:
- defense costs can pressure operating margins;
- settlements or verdicts can create episodic cash outflows;
- adverse publicity can affect physician and patient adoption;
- label changes or additional warnings could affect demand;
- insurance coverage and reserves can influence reported earnings.
Publicly reported litigation involving Paragard has included multidistrict and coordinated product-liability proceedings. The economic impact depends on claim inventories, dismissal rates, settlement structures, trial outcomes, insurance recovery, and the company’s reserves.[5]
What generic entry risks exist for Paragard?
A traditional generic launch scenario does not apply. The relevant threat is a competing copper-IUD device receiving FDA authorization.
| Entry factor |
Risk to Paragard |
| Core patent expiry |
Low legal protection from the original technology |
| FDA approval burden |
High |
| Clinical evidence burden |
Moderate to high, depending on design and pathway |
| Manufacturing complexity |
Moderate to high |
| Physician switching |
Moderate |
| Brand loyalty |
Meaningful |
| Reimbursement differentiation |
Variable |
| Litigation risk |
High product-liability sensitivity |
| Price erosion |
Possible if multiple approved devices enter |
A competitor could pressure Paragard through lower acquisition cost, improved inserter design, reduced cramping or bleeding claims, better insertion training, or stronger payer contracting. However, copper-IUD demand is not purely price-driven. Provider confidence and ease of insertion are important purchasing factors.
How strong is the Paragard commercial moat?
Paragard has a moderate commercial moat and a weak-to-moderate patent moat.
Its commercial strengths include:
- more than 40 years of U.S. market experience;
- established physician familiarity;
- a differentiated hormone-free profile;
- long duration of use;
- emergency-contraception utility;
- entrenched distribution and training infrastructure;
- limited direct U.S. copper-IUD competition.
Its weaknesses include:
- no conventional drug exclusivity;
- mature core technology;
- adverse bleeding and cramping profile;
- exposure to breakage and removal litigation;
- lack of separately disclosed product financials;
- competition from better-funded hormonal IUD franchises;
- dependence on clinician insertion capacity.
The franchise is defensible, but its durability depends more on execution and trust than on patent exclusion.
What generic or competing launch scenarios are most likely?
The most plausible competitive scenarios are:
No meaningful U.S. entrant
Paragard retains its position because the copper-IUD market is specialized, clinical-development returns are uncertain, and regulatory and litigation costs discourage entry.
A differentiated copper-IUD entrant
A competitor launches a device with an improved insertion system, alternative copper geometry, a different duration claim, or a more favorable bleeding profile. This would create the greatest strategic pressure.
Price-led institutional competition
A competitor wins contracts with public-health clinics, Medicaid providers, or large reproductive-health networks through lower acquisition cost. This could reduce Paragard pricing without immediately displacing the brand in private practice.
Hormonal-IUD substitution
The largest ongoing threat remains patient and clinician movement toward levonorgestrel IUDs, particularly when menstrual suppression is a priority.
What is the investment and licensing outlook for Paragard?
Paragard is more likely to be valued as an established cash-flow asset than as a platform for major pipeline expansion. Licensing value would depend on geographic rights, manufacturing partnerships, public-sector distribution, or product improvements rather than on a new molecular patent estate.
Potential commercial levers include international expansion, improved clinician training, broader emergency-contraception adoption, payer access, and next-generation copper-IUD designs. The main transaction risks are product-liability reserves, regulatory obligations, and the inability to verify standalone product economics from public filings.
Key Takeaways
- Paragard T 380A is a copper IUD and medical device, not a conventional pharmaceutical drug.
- CooperSurgical acquired the product from Teva for approximately $1.1 billion in 2017.
- Paragard has no conventional Orange Book exclusivity or Paragraph IV litigation framework.
- The core technology is mature, so current commercial protection comes from regulation, manufacturing, brand familiarity, and distribution.
- Standalone revenue and profit are not publicly disclosed.
- Hormonal IUDs are the main commercial competitors.
- The largest legal exposure is product-liability litigation involving alleged breakage and removal injuries.
- The most credible entry threat is a newly authorized copper-IUD device with a better safety, insertion, bleeding, pricing, or reimbursement profile.
- Paragard is a durable franchise but does not have the patent strength of a newly launched pharmaceutical product.
FAQs About Paragard T 380A Market and Exclusivity
Is Paragard a pharmaceutical drug?
No. Paragard is an FDA-approved Class III intrauterine contraceptive medical device.
Does Paragard have an Orange Book patent?
No. The Orange Book applies to approved drug products, while Paragard is regulated under the FDA medical-device framework.
Who owns Paragard?
CooperSurgical, a subsidiary of Cooper Companies, owns and markets Paragard in the United States.
Can a generic version of Paragard launch automatically?
No. A competing manufacturer cannot use a conventional generic-drug approval or Paragraph IV certification. It must obtain the applicable FDA authorization for its own copper-IUD device.
What is the main financial risk to Paragard?
The principal financial risks are product-liability costs, declining preference for copper contraception relative to hormonal IUDs, limited public visibility into standalone revenue, and entry by a differentiated competing copper-IUD device.
References
- CooperSurgical, Inc. (2023). Paragard T 380A copper intrauterine contraceptive: Prescribing information.
- U.S. Food and Drug Administration. (1984). PMA P840001: Paragard T 380A intrauterine copper contraceptive. FDA Devices@FDA database.
- Teva Pharmaceutical Industries Ltd. (2017). Teva announces agreement to divest Paragard contraceptive business to CooperSurgical.
- The Cooper Companies, Inc. (2023). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
- U.S. Judicial Panel on Multidistrict Litigation. (2021). In re: Paragard IUD Products Liability Litigation, MDL No. 2974.
